Kevin M Shannon

List of Publications by Year
in descending order

177	12,856	25034	24982
papers	citations	57 h-index	109 g-index

182	182	182	13544
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Hyperactive Ras in developmental disorders and cancer. Nature Reviews Cancer, 2007, 7, 295-308.	28.4	1,422
2	Germline KRAS mutations cause Noonan syndrome. Nature Genetics, 2006, 38, 331-336.	21.4	670
3	Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nature Genetics, 1996, 12, 144-148.	21.4	555
4	Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nature Genetics, 2008, 40, 600-608.	21.4	514
5	Loss of The Normal NF1 Allele from the Bone Marrow of Children with Type 1 Neurofibromatosis and Malignant Myeloid Disorders. New England Journal of Medicine, 1994, 330, 597-601.	27.0	423
6	Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood, 2004, 103, 2325-2331.	1.4	415
7	Homozygous Inactivation of theNF1Gene in Bone Marrow Cells from Children with Neurofibromatosis Type 1 and Malignant Myeloid Disorders. New England Journal of Medicine, 1997, 336, 1713-1720.	27.0	285
8	Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 597-602.	7.1	279
9	MLL3 Is a Haploinsufficient 7q Tumor Suppressor in Acute Myeloid Leukemia. Cancer Cell, 2014, 25, 652-665.	16.8	274
10	Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood, 2009, 114, 1859-1863.	1.4	260
11	Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Blood, 2008, 111, 1044-1053.	1.4	259
12	Myelodysplastic and Myeloproliferative Disorders of Childhood: A Study of 167 Patients. Blood, 1999, 93, 459-466.	1.4	221
13	Single-Cell Profiling Identifies Aberrant STAT5 Activation in Myeloid Malignancies with Specific Clinical and Biologic Correlates. Cancer Cell, 2008, 14, 335-343.	16.8	219
14	Mutations of the NF1 Gene in Children With Juvenile Myelomonocytic Leukemia Without Clinical Evidence of Neurofibromatosis, Type 1. Blood, 1998, 92, 267-272.	1.4	190
15	AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. Cell Stem Cell, 2018, 23, 86-100.e6.	11.1	189
16	Targeting oncogenic Ras signaling in hematologic malignancies. Blood, 2012, 120, 3397-3406.	1.4	171
17	Genetic and Biochemical Evidence That Haploinsufficiency of the Nf1 Tumor Suppressor Gene Modulates Melanocyte and Mast Cell Fates in Vivo. Journal of Experimental Medicine, 2000, 191, 181-188.	8.5	168
18	Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood, 2004, 103, 4243-4250.	1.4	162

#	Article	IF	Citations
19	Disruption of the Mouse Rce1 Gene Results in Defective Ras Processing and Mislocalization of Ras within Cells. Journal of Biological Chemistry, 1999, 274, 8383-8390.	3.4	161
20	p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes and Development, 2010, 24, 1389-1402.	5.9	148
21	KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer. Cell, 2017, 168, 817-829.e15.	28.9	148
22	Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Nature, 2009, 461, 411-414.	27.8	141
23	Nf1 Regulates Hematopoietic Progenitor Cell Growth and Ras Signaling in Response to Multiple Cytokines. Journal of Experimental Medicine, 1998, 187, 1893-1902.	8.5	140
24	Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells. Blood, 2005, 106, 311-317.	1.4	138
25	Recombinant human erythropoietin in the anemia of prematurity: Results of a placebo-controlled pilot study. Journal of Pediatrics, 1991, 118, 949-955.	1.8	132
26	Nf1 and Gmcsf Interact in Myeloid Leukemogenesis. Molecular Cell, 2000, 5, 189-195.	9.7	132
27	Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Blood, 2011, 117, 2022-2032.	1.4	132
28	Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. , 1999, 89, 14-22.		119
29	Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. Journal of Clinical Investigation, 2013, 123, 335-339.	8.2	119
30	Circulating Erythroid Progenitors in the Anemia of Prematurity. New England Journal of Medicine, 1987, 317, 728-733.	27.0	117
31	GTPase activating proteins: critical regulators of intracellular signaling. Biochimica Et Biophysica Acta: Reviews on Cancer, 2002, 1602, 23-45.	7.4	117
32	Deregulated Ras signaling in developmental disorders: new tricks for an old dog. Current Opinion in Genetics and Development, 2007, 17, 15-22.	3.3	109
33	SHP-2 and myeloid malignancies. Current Opinion in Hematology, 2004, 11, 44-50.	2.5	106
34	Inherited predispositions and hyperactive Ras in myeloid leukemogenesis. Pediatric Blood and Cancer, 2006, 46, 579-585.	1.5	103
35	K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells. Blood, 2007, 109, 3945-3952.	1.4	103
36	Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness. Nature, 2013, 504, 143-147.	27.8	101

#	Article	IF	Citations
37	Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial. Clinical Cancer Research, 2014, 20, 490-498.	7.0	99
38	MLL5, a homolog of Drosophila trithorax located within a segment of chromosome band 7q22 implicated in myeloid leukemia. Oncogene, 2002, 21, 4849-4854.	5.9	92
39	Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells. PLoS Biology, 2009, 7, e1000059.	5.6	89
40	Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer Cell, 2004, 6, 547-552.	16.8	87
41	Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells. Blood, 2011, 117, 4253-4261.	1.4	82
42	In Vitro and In Vivo Effects of a Farnesyltransferase Inhibitor onNf1-Deficient Hematopoietic Cells. Blood, 1999, 94, 2469-2476.	1.4	81
43	A MEK Inhibitor Abrogates Myeloproliferative Disease in Kras Mutant Mice. Science Translational Medicine, 2011, 3, 76ra27.	12.4	81
44	Biochemical and Functional Characterization of Germ Line KRAS Mutations. Molecular and Cellular Biology, 2007, 27, 7765-7770.	2.3	80
45	Enhancement of erythropoiesis by recombinant human erythropoietin in low birth weight infants: A pilot study. Journal of Pediatrics, 1992, 120, 586-592.	1.8	79
46	Juvenile myelomonocytic leukemia: molecular understanding and prospects for therapy. Trends in Molecular Medicine, 1996, 2, 468-475.	2.6	79
47	Preclinical efficacy of MEK inhibition in Nras-mutant AML. Blood, 2014, 124, 3947-3955.	1.4	79
48	The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. Nature Medicine, 2017, 23, 301-313.	30.7	79
49	Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1. , 1997, 79, 1438-1446.		78
50	Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies. Blood, 2006, 108, 1684-1689.	1.4	78
51	Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer. Cancer Cell, 2018, 34, 852-862.e4.	16.8	73
52	Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes. JCI Insight, 2018, 3, .	5.0	71
53	Acute leukemia: A pediatric perspective. Cancer Cell, 2002, 2, 437-445.	16.8	68
54	Resistance in the land of molecular cancer therapeutics. Cancer Cell, 2002, 2, 99-102.	16.8	66

#	Article	IF	Citations
55	Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras. Blood, 2012, 119, 1032-1035.	1.4	66
56	RAS,FLT3, andTP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7. Genes Chromosomes and Cancer, 2004, 39, 217-223.	2.8	62
57	Mll5 contributes to hematopoietic stem cell fitness and homeostasis. Blood, 2009, 113, 1455-1463.	1.4	62
58	Hyperactivation of protein kinase B and ERK have discrete effects on survival, proliferation, and cytokine expression in Nf1-deficient myeloid cells. Cancer Cell, 2002, 2, 507-514.	16.8	60
59	Mutant Ikzf1, Kras ^{G12D} , and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 5106-5111.	7.1	60
60	Dominant Role of Oncogene Dosage and Absence of Tumor Suppressor Activity in Nras-Driven Hematopoietic Transformation. Cancer Discovery, 2013, 3, 993-1001.	9.4	60
61	Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia. Nature, 2014, 513, 512-516.	27.8	60
62	Harnessing preclinical mouse models to inform human clinical cancer trials. Journal of Clinical Investigation, 2006, 116, 847-852.	8.2	59
63	Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia. Journal of Experimental Medicine, 2010, 207, 2581-2594.	8.5	58
64	Targeting Ras in Myeloid Leukemias. Clinical Cancer Research, 2008, 14, 2249-2252.	7.0	57
65	Myeloid Malignancies Induced by Alkylating Agents in Nf1 Mice. Blood, 1999, 93, 3617-3623.	1.4	55
66	Biochemical Characterization of a Novel KRAS Insertion Mutation from a Human Leukemia. Journal of Biological Chemistry, 1996, 271, 32491-32494.	3.4	54
67	A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene. Blood, 2009, 113, 1075-1085.	1.4	54
68	Transient monosomy 7. , 1999, 85, 2655-2661.		51
69	Isolation and analysis of candidate myeloid tumor suppressor genes from a commonly deleted segment of 7q22. Genomics, 2005, 85, 600-607.	2.9	49
70	Germline Mutations in Components of the Ras Signaling Pathway in Noonan Syndrome and Related Disorders. Cell Cycle, 2006, 5, 1607-1611.	2.6	49
71	ABHD17 regulation of plasma membrane palmitoylation and N-Ras-dependent cancer growth. Nature Chemical Biology, 2021, 17, 856-864.	8.0	49
72	Evidence that juvenile myelomonocytic leukemia can arise from a pluripotential stem cell. Blood, 2000, 96, 2310-2313.	1.4	48

#	Article	IF	Citations
73	Mutation analysis in Costello syndrome: functional and structural characterization of theHRASp.Lys117Arg mutation. Human Mutation, 2008, 29, 232-239.	2.5	48
74	Abnormal hematopoiesis in Gab2 mutant mice. Blood, 2007, 110, 116-124.	1.4	47
75	Dysregulated RasGRP1 Responds to Cytokine Receptor Input in T Cell Leukemogenesis. Science Signaling, 2013, 6, ra21.	3.6	45
76	Candidate Gene Isolation and Comparative Analysis of a Commonly Deleted Segment of 7q22 Implicated in Myeloid Malignancies. Genomics, 2001, 77, 171-180.	2.9	43
77	Therapy-induced malignant neoplasms in Nf1 mutant mice. Cancer Cell, 2005, 8, 337-348.	16.8	43
78	Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo. Blood, 2006, 108, 2041-2044.	1.4	41
79	Targeting oncogenic Ras. Genes and Development, 2007, 21, 1989-1992.	5.9	41
80	KRAS Engages AGO2 to Enhance Cellular Transformation. Cell Reports, 2016, 14, 1448-1461.	6.4	41
81	Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis. Nature Genetics, 2015, 47, 539-543.	21.4	39
82	Quantitative effects of Nf1 inactivation on in vivo hematopoiesis. Journal of Clinical Investigation, 2001, 108, 709-715.	8.2	39
83	Do terminal deletions of 11q23 exist? Identification of undetected translocations with fluorescence in situ hybridization. Genes Chromosomes and Cancer, 1993, 7, 204-208.	2.8	37
84	Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes. Journal of Clinical Investigation, 2020, 130, 863-876.	8.2	36
85	Ras processing as a therapeutic target in hematologic malignancies. Current Opinion in Hematology, 2002, 9, 308-315.	2.5	33
86	RAS mutations in pediatric leukemias withMLL gene rearrangements. , 1998, 21, 270-275.		32
87	Genomic structure of the PIK3CG gene on chromosome band 7q22 and evaluation as a candidate myeloid tumor suppressor. Blood, 2002, 99, 372-374.	1.4	32
88	Age-Related Differences in Erythropoietic Response to Recombinant Human Erythropoietin: Comparison in Adult and Infant Rhesus Monkeys. Pediatric Research, 1990, 28, 567-571.	2.3	31
89	JAKing up hematopoietic proliferation. Cancer Cell, 2005, 7, 291-293.	16.8	31
90	MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus. Neuro-Oncology, 2022, 24, 1845-1856.	1.2	30

#	Article	IF	Citations
91	Dose-Dependent Effects of Focal Fractionated Irradiation on Secondary Malignant Neoplasms in Nf1 Mutant Mice. Cancer Research, 2011, 71, 106-115.	0.9	28
92	The Ras signaling pathway and the molecular basis of myeloid leukemogenesis. Current Opinion in Hematology, 1995, 2, 305-308.	2.5	27
93	De novo HRAS and KRAS mutations in two siblings with short stature and neuro-cardio-facio-cutaneous features. Journal of Medical Genetics, 2007, 44, e84-e84.	3.2	27
94	Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia. Leukemia, 2020, 34, 2025-2037.	7.2	27
95	Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo. Blood, 2013, 121, 4884-4893.	1.4	26
96	Implantation techniques and outcomes after cardiac resynchronization therapy for congenitally corrected transposition of the great arteries. Heart Rhythm, 2018, 15, 1808-1815.	0.7	26
97	Î² common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice. Blood, 2007, 109, 1687-1691.	1.4	25
98	Molecular evidence that childhood monosomy 7 syndrome is distinct from juvenile chronic myelogenous leukemia and other childhood myeloproliferative disorders. Genes Chromosomes and Cancer, 1995, 12, 50-57.	2.8	24
99	Use of chromosome engineering to model a segmental deletion of chromosome band 7q22 found in myeloid malignancies. Blood, 2010, 115, 4524-4532.	1.4	24
100	NRAS G12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemia. Blood, 2014, 124, 3274-3283.	1.4	24
101	Recombinant Human Erythropoietin in Neonatal Anemia. Clinics in Perinatology, 1995, 22, 627-640.	2.1	23
102	Mouse cancer models as a platform for performing preclinical therapeutic trials. Current Opinion in Genetics and Development, 2003, 13, 84-89.	3.3	22
103	A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies. Cancer Research, 2017, 77, 5706-5711.	0.9	22
104	Hematologic effects of inactivating the Ras processing enzymeRce1. Blood, 2003, 101, 2250-2252.	1.4	20
105	Sending out an SOS. Nature Genetics, 2007, 39, 8-9.	21.4	19
106	Catheter Ablation of Ventricular Arrhythmia for Ebstein's Anomaly in Unoperated and Post-Surgical Patients. JACC: Clinical Electrophysiology, 2018, 4, 1300-1307.	3.2	19
107	Genetic disruption of N-RasG12D palmitoylation perturbs hematopoiesis and prevents myeloid transformation in mice. Blood, 2020, 135, 1772-1782.	1.4	18
108	Functional evidence implicating chromosome 7q22 haploinsufficiency in myelodysplastic syndrome pathogenesis. ELife, 2015, 4, .	6.0	17

#	Article	IF	Citations
109	Hay in a haystack. Nature, 2008, 451, 252-253.	27.8	16
110	CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition. PLoS ONE, 2019, 14, e0220026.	2.5	16
111	Modeling myeloid leukemia tumor suppressor gene inactivation in the mouse. Seminars in Cancer Biology, 2001, 11, 191-199.	9.6	15
112	IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 11630-11635.	7.1	15
113	KRAS insertion mutations are oncogenic and exhibit distinct functional properties. Nature Communications, 2016, 7, 10647.	12.8	15
114	Role of the NF1 Gene in Leukemogenesis and Myeloid Growth Control. Journal of Pediatric Hematology/Oncology, 1997, 19, 551-554.	0.6	14
115	Leukemic potential of doubly mutant Nf1 andWv hematopoietic cells. Blood, 2003, 101, 1984-1986.	1.4	14
116	Genetics, Epigenetics, and Leukemia. New England Journal of Medicine, 2010, 363, 2460-2461.	27.0	14
117	Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency. Haematologica, 2016, 101, 1190-1199.	3.5	14
118	Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy. PLoS ONE, 2018, 13, e0193849.	2.5	14
119	Recombinant Erythropoietin in Anemia of Prematurity: Five Years Later. Pediatrics, 1993, 92, 614-617.	2.1	14
120	Molecular analysis at theNF1 locus in astrocytic brain tumors. Cancer, 1995, 76, 674-677.	4.1	12
121	PLC-Î³ and PI3K Link Cytokines to ERK Activation in Hematopoietic Cells with Normal and Oncogenic Kras. Science Signaling, 2013, 6, ra105.	3.6	12
122	Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke. BMC Cancer, 2014, 14, 6.	2.6	12
123	Mutations in GATA2 are rare in juvenile myelomonocytic leukemia. Blood, 2014, 123, 1426-1427.	1.4	12
124	KrasP34R and KrasT58I mutations induce distinct RASopathy phenotypes in mice. JCI Insight, 2020, 5, .	5.0	10
125	Recombinant Erythopoietin in Pediatrics: A Clinical Perspective. Pediatric Annals, 1990, 19, 197-206.	0.8	10
126	Leukemic Transformation in Patients With Severe Congenital Neutropenia. The American Journal of Pediatric Hematology/oncology, 2001, 23, 487-495.	1.3	9

#	Article	IF	Citations
127	High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality Predictions. Cell Reports, 2019, 27, 631-647.e5.	6.4	9
128	Granulocyte/macrophage colony-stimulating factor and accessory cells modulate radioprotection by purified hematopoietic cells. Journal of Experimental Medicine, 2005, 201, 853-858.	8.5	8
129	Tumor suppressor gene inactivation in myeloid malignancies. Best Practice and Research in Clinical Haematology, 2008, 21, 601-614.	1.7	8
130	Resistant T-Cell Acute Lymphoblastic Leukemias That Emerge after In Vivo Treatment with Dexamethasone Frequently Down-Regulate Glucocorticoid Receptor Protein Expression. Blood, 2016, 128, 753-753.	1.4	7
131	Myeloid Malignancies Induced by Alkylating Agents in Nf1 Mice. Blood, 1999, 93, 3617-3623.	1.4	6
132	Oncogenic Ras scales the ALPS. Blood, 2011, 117, 2747-2748.	1.4	5
133	A(nother) RAF mutation in LCH. Blood, 2014, 123, 3063-3065.	1.4	5
134	Convergent genetic aberrations in murine and human T lineage acute lymphoblastic leukemias. PLoS Genetics, 2019, 15, e1008168.	3.5	5
135	Myelodysplastic and Myeloproliferative Disorders of Childhood: A Study of 167 Patients. Blood, 1999, 93, 459-466.	1.4	5
136	Acute Myeloid Leukemia Associated With t(8;21) or Trisomy 8 in Children With Neurofibromatosis, Type 1. Journal of Pediatric Hematology/Oncology, 2003, 25, 343.	0.6	4
137	The sum is greater than the FGFR1 partner. Cancer Cell, 2004, 5, 203-204.	16.8	4
138	De novo HRAS and KRAS mutations in two siblings with short stature and neuro-cardio-facio-cutaneous features. BMJ Case Reports, 2009, 2009, bcr0720080550-bcr0720080550.	0.5	4
139	Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a031526.	6.2	3
140	Nf1-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK. Molecular Cancer Therapeutics, 2020, 19, 2382-2395.	4.1	3
141	Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1. Cancer, 1997, 79, 1438-1446.	4.1	3
142	Combination of a MEK Inhibitor, AZD6244, and Dual PI3K/mTOR Inhibitor, NVP-BEZ235: An Effective Therapeutic Strategy for Acute Myeloid Leukemia. Blood, 2010, 116, 3978-3978.	1.4	3
143	Advancing the STATus of MPN pathogenesis. Blood, 2012, 119, 3374-3376.	1.4	2
144	Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. American Journal of Medical Genetics Part A, 1999, 89, 14-22.	2.4	2

#	Article	IF	Citations
145	Germline Mutations in CBL Cause a Predisposition to Juvenile Myelomonocytic Leukemia.. Blood, 2009, 114, 310-310.	1.4	2
146	Evidence that juvenile myelomonocytic leukemia can arise from a pluripotential stem cell. Blood, 2000, 96, 2310-2313.	1.4	2
147	Chemical proteomic analysis of palmostatin beta-lactone analogs that affect N-Ras palmitoylation. Bioorganic and Medicinal Chemistry Letters, 2021, 53, 128414.	2.2	2
148	Heritable predispositions to childhood hematologic malignancies. , 0, , 362-388.		2
149	Rationale for Using Recombinant Human Erythropoietin to Treat the Anemia of Prematurity. Contributions To Nephrology, 1989, 76, 324-329.	1.1	1
150	Genetic Predispositions and Childhood Cancer. Environmental Health Perspectives, 1998, 106, 801.	6.0	1
151	Reconsidering how we treat severe congenital neutropenia. Blood, 2006, 107, 4575-4576.	1.4	1
152	More than kin and less than kind. Nature, 2009, 460, 805-807.	27.8	1
153	Soil and Seed: Coconspirators in Therapy-Induced Myeloid Neoplasms. Blood Cancer Discovery, 2020, 1, 10-12.	5.0	1
154	NF1 Mutations in Hematologic Cancers. , 2012, , 469-485.		1
155	Treatment with a MEK Inhibitor Improves Myeloproliferation, Anemia and Survival in a Mouse Model of CMML and JMML.. Blood, 2009, 114, 966-966.	1.4	1
156	Kras G12D Expression in Hematopoietic Stem/Progenitor Cells Initiates T Cell Acute Lymphoblastic Leukemia/Lymphoma.. Blood, 2007, 110, 153-153.	1.4	1
157	The PI3K Inhibitor GDC-0941 Attenuates Disease in a KrasG12D Mouse Model of CMML and JMML.. Blood, 2012, 120, 2862-2862.	1.4	1
158	A â€œRas-in-ALLâ€•model of signaling?. Blood, 2004, 104, 297-298.	1.4	0
159	The SPS Affair: A Complex Tale of Illicit Proliferation. Cancer Cell, 2009, 16, 87-88.	16.8	0
160	Genetic Dissection of Cooperating Mutations in BXH-2 Acute Myeloid Leukemia with and without Nf1 Gene Mutation.. Blood, 2004, 104, 2567-2567.	1.4	0
161	Novel Germ Line Mutations in the KRAS2 Gene Cause Noonan Syndrome and Deregulate Hematopoietic Cell Growth.. Blood, 2005, 106, 1602-1602.	1.4	0
162	Intracellular Signals as Molecular Biomarkers for Therapeutic Responses in Kras Mutant Myeloid Cells.. Blood, 2007, 110, 2196-2196.	1.4	0

#	Article	IF	Citations
163	Bcl11a Causes p21Cip1 Down-Regulation and Transplantable Leukemia in Nf1-Deficient Mice.. Blood, 2007, 110, 2657-2657.	1.4	0
164	Leukemogenic K-RasG12D Induces Cell Cycle Entry and Clonal Dominance in Hematopoietic Stem Cells.. Blood, 2007, 110, 778-778.	1.4	0
165	PI3 Kinase, Phospholipase C (PLC)-Î³, and RasGRPs Act Cooperatively to Activate the Ras-Extracellular-Related Kinase (ERK) Pathway in Response to Cytokines in Normal and Kras Mutant Myeloid Cells.. Blood, 2009, 114, 2512-2512.	1.4	0
166	Oncogene Withdrawal Selectively Alters Phosphoprotein States and Shifts Differentiation Status In Myeloid Leukemia Subpopulations. Blood, 2010, 116, 3160-3160.	1.4	0
167	Akt Activation Is Important In KRAS-Mediated Multistep Leukemogenesis. Blood, 2010, 116, 4200-4200.	1.4	0
168	Heterozygous Germ Line Deletion of a 2Mb Interval in Mice That Models Loss of 7q22 in Human Myeloid Malignancies Results in Defective Hematopoietic Stem Cell Function Reminiscent of Premature Aging. Blood, 2011, 118, 2340-2340.	1.4	0
169	Delineating Critical Effectors of Remission Induction in a Mouse Model of AML. Blood, 2011, 118, 5232-5232.	1.4	0
170	Mechanisms of Relapse Following Targeted Therapy in An NRASG12V and Mll-AF9 Driven Mouse Model of AML. Blood, 2011, 118, 2620-2620.	1.4	0
171	Activated NRAS Mediates Self-Renewal Capacity in AML by Facilitating the Mll/AF9-Specified Gene Expression Signature. Blood, 2012, 120, 5116-5116.	1.4	0
172	Oncogenic Nras Increases Hematopoietic Stem Cell Proliferation and Self-Renewal Through a Bimodal Effect. Blood, 2012, 120, 119-119.	1.4	0
173	Identification of CKMT1B As a New Target in EVI1-Positive AML. Blood, 2015, 126, 3674-3674.	1.4	0
174	Targeting the Creatine Kinase Pathway in EVI1-Positive Acute Myeloid Leukemia. Blood, 2016, 128, 523-523.	1.4	0
175	Response and Resistance to Bromodomain Inhibition in AML Driven By Hyperactive Ras Signaling. Blood, 2016, 128, 1654-1654.	1.4	0
176	Glucocorticoids Paradoxically Induce Intrinsic Steroid Resistance through a STAT5-Mediated Survival Mechanism in T-Cell Acute Lymphoblastic Leukemia. Blood, 2018, 132, 913-913.	1.4	0
177	Co-Targeting BET Bromodomain Proteins and Aberrant Signaling in AML. Blood, 2020, 136, 5-6.	1.4	0